Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousTreatment OutcomeRetrospective StudiesTissue DonorsGraft vs Leukemia EffectLeukemiaMyeloablative AgonistsChimerismHistocompatibilityHematologic DiseasesHistocompatibility TestingBusulfanTransplantation ChimeraMycosesWhole-Body IrradiationHepatic Veno-Occlusive DiseaseVidarabineRecurrenceCytomegalovirus InfectionsAspergillosisCord Blood Stem Cell TransplantationGraft vs Tumor EffectAntilymphocyte SerumSurvival AnalysisSiblingsPeripheral Blood Stem Cell TransplantationDonor SelectionSevere Combined ImmunodeficiencyLeukemia, Myeloid, AcuteBone Marrow TransplantationImmunocompromised HostLymphoproliferative DisordersAcute DiseaseStem Cell TransplantationMyelodysplastic SyndromesTime FactorsEuropeFollow-Up StudiesLymphohistiocytosis, HemophagocyticBronchiolitis ObliteransTransplantationSurvival RateImmunosuppressive AgentsHLA AntigensOpportunistic InfectionsPrecursor Cell Lymphoblastic Leukemia-LymphomaGraft SurvivalDisease-Free SurvivalAnemia, AplasticRisk FactorsRemission InductionCytomegalovirusCystitisEnzyme Replacement TherapyThermometryTransplantation ImmunologyLymphocyte DepletionT-LymphocytesStomatitisCombined Modality TherapyImmunosuppressionSurvivorsMediterranean RegionNeoplasmsProspective StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCyclophosphamideRoseolovirus InfectionsReceptors, KIRGanciclovirPlatelet TransfusionAntifungal AgentsCohort StudiesAdjustment DisordersMucositisBK VirusLeukemia, MyeloidIncidenceSalvage TherapyHemoglobinopathiesAntiviral AgentsPrognosisMinor Histocompatibility AntigensOrgan TransplantationAutoimmune DiseasesIron OverloadNeutropeniaPolyomavirus InfectionsVirus ActivationTransplantation, IsogeneicAdenovirus Infections, HumanEpstein-Barr Virus InfectionsLiving DonorsLung Diseases, FungalAdenoviridae Infections